Dr. Anthony Joshua completed his medical oncology training at the Royal Prince Alfred hospital in Sydney, Australia before moving to Toronto to complete a PhD under the supervision of Dr. Jeremy Squire in prostatic carcinogenesis. He has since joined the Department of Medical Oncology at Princess Margaret Hospital, specialising in genito-urinary malignancy and melanoma. He is currently an Assistant Professor with the University of Toronto and a clinician-scientist at the University Health Network.
His current research interests include the unfolded protein response (working with Dr. Brad Wouters), autophagy in prostatic carcinogenesis, translational research in GU and melanoma trials and clinical trial design. He also has an interest in epistemiology in medicine.
Ann Oncol. 2018 Apr 10;:
Clin Cancer Res. 2018 Apr 03;:
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).
J Clin Oncol. 2018 Mar 12;:JCO2017741090
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Urol Oncol. 2018 Feb 14;:
Clin Cancer Res. 2017 May 01;23(9):2169-2176
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
J Clin Oncol. 2017 Dec 28;:JCO2017756270
Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer.
Future Sci OA. 2018 Jan;4(1):FSO253
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
Invest New Drugs. 2017 Dec 18;:
Cancer Res. 2017 Sep 15;:
Support Care Cancer. 2017 Jul 25;:
Principal Investigator, Princess Margaret Cancer Centre
Assistant Professor, Department of Medicine, University of Toronto